IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-12456-3.html
   My bibliography  Save this article

Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders

Author

Listed:
  • Naoya Uchida

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

  • Matthew M. Hsieh

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

  • Lydia Raines

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

  • Juan J. Haro-Mora

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

  • Selami Demirci

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

  • Aylin C. Bonifacino

    (NHLBI, NIH)

  • Allen E. Krouse

    (NHLBI, NIH)

  • Mark E. Metzger

    (NHLBI, NIH)

  • Robert E. Donahue

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

  • John F. Tisdale

    (National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH)
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH)

Abstract

Hematopoietic stem cell (HSC) gene therapy is being evaluated for hemoglobin disorders including sickle cell disease (SCD). Therapeutic globin vectors have demanding requirements including high-efficiency transduction at the HSC level and high-level, erythroid-specific expression with long-term persistence. The requirement of intron 2 for high-level β-globin expression dictates a reverse-oriented globin-expression cassette to prevent its loss from RNA splicing. Current reverse-oriented globin vectors can drive phenotypic correction, but they are limited by low vector titers and low transduction efficiencies. Here we report a clinically relevant forward-oriented β-globin-expressing vector, which has sixfold higher vector titers and four to tenfold higher transduction efficiency for long-term hematopoietic repopulating cells in humanized mice and rhesus macaques. Insertion of Rev response element (RRE) allows intron 2 to be retained, and β-globin production is observed in transplanted macaques and human SCD CD34+ cells. These findings bring us closer to a widely applicable gene therapy for hemoglobin disorders.

Suggested Citation

  • Naoya Uchida & Matthew M. Hsieh & Lydia Raines & Juan J. Haro-Mora & Selami Demirci & Aylin C. Bonifacino & Allen E. Krouse & Mark E. Metzger & Robert E. Donahue & John F. Tisdale, 2019. "Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders," Nature Communications, Nature, vol. 10(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12456-3
    DOI: 10.1038/s41467-019-12456-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-12456-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-12456-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Naoya Uchida & Ulana Stasula & Selami Demirci & Paula Germino-Watnick & Malikiya Hinds & Anh Le & Rebecca Chu & Alexander Berg & Xiong Liu & Ling Su & Xiaolin Wu & Allen E. Krouse & N. Seth Linde & Ay, 2023. "Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model," Nature Communications, Nature, vol. 14(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12456-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.